The stock of Actuate Therapeutics Inc (ACTU) has gone up by 13.23% for the week, with a -32.41% drop in the past month and a -4.63% drop in the past quarter. The volatility ratio for the week is 14.26%, and the volatility levels for the past 30 days are 10.94% for ACTU. The simple moving average for the past 20 days is -12.12% for ACTU’s stock, with a -19.82% simple moving average for the past 200 days.
Is It Worth Investing in Actuate Therapeutics Inc (NASDAQ: ACTU) Right Now?
Analysts have mixed views on the stock, with 2 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for ACTU is 5.83M, and currently, short sellers hold a 4.14% ratio of that float. The average trading volume of ACTU on July 04, 2025 was 92.85K shares.
ACTU stock’s latest price update
Actuate Therapeutics Inc (NASDAQ: ACTU)’s stock price has decreased by -2.23% compared to its previous closing price of $6.74. However, the company has seen a 13.23% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-24 that – Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone
Analysts’ Opinion of ACTU
Many brokerage firms have already submitted their reports for ACTU stocks, with Craig Hallum repeating the rating for ACTU by listing it as a “Buy”. The predicted price for ACTU in the upcoming period, according to Craig Hallum is $21 based on the research report published on April 22, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ACTU reach a price target of $20. The rating they have provided for ACTU stocks is “Buy” according to the report published on March 17th, 2025.
ACTU Trading at -26.52% from the 50-Day Moving Average
After a stumble in the market that brought ACTU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.04% of loss for the given period.
Volatility was left at 10.94%, however, over the last 30 days, the volatility rate increased by 14.26%, as shares sank -27.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.65% lower at present.
During the last 5 trading sessions, ACTU rose by +13.23%, which changed the moving average for the period of 200-days by -17.73% in comparison to the 20-day moving average, which settled at $7.50. In addition, Actuate Therapeutics Inc saw N/A in overturn over a single year, with a tendency to cut further N/A.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACTU starting from Bios Equity COF, LP, who purchase 71,428 shares at the price of $7.00 back on Jun 27 ’25. After this action, Bios Equity COF, LP now owns 196,428 shares of Actuate Therapeutics Inc, valued at $499,996 using the latest closing price.
Kreis Leslie W., the Director of Actuate Therapeutics Inc, purchase 71,428 shares at $7.00 during a trade that took place back on Jun 27 ’25, which means that Kreis Leslie W. is holding 196,428 shares at $499,996 based on the most recent closing price.
Stock Fundamentals for ACTU
The total capital return value is set at 5.09%.
Currently, EBITDA for the company is -25.16 million with net debt to EBITDA at 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.46.
Conclusion
To put it simply, Actuate Therapeutics Inc (ACTU) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
